An open-label, multicenter phase Ib clinical trial of A166 for injection for the treatment of patients with HER2-positive unresectable locally advanced, recurrent, or metastatic colorectal cancer who have failed or are intolerant to second-line or higher standard therapy
Latest Information Update: 31 Oct 2025
At a glance
- Drugs Trastuzumab botidotin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
Most Recent Events
- 31 Oct 2025 New trial record